Novo Nordisk A/S: Xultophy(r) (IDegLira) approved
Post# of 301275
Posted On: 09/18/2014 2:30:15 PM
Novo Nordisk A/S: Xultophy(r) (IDegLira) approved in Europe
BAGSVAERD, Denmark, Sept. 18, 2014 (GLOBE NEWSWIRE) -- Novo Nordisk today announced that the European Commission has granted marketing authorisation for Xultophy ® for the treatment of type 2 diabetes mellitus in adults. The authorisation covers all 27 European Union member states.
For further information
| Media: | ||
| Mike Rulis | +45 3079 3573 | mike@novonordisk.com |
| Ken Inchausti (US) | +1 609 514 8316 | kiau@novonordisk.com |
| Investors: | ||
| Kasper Roseeuw Poulsen | +45 3079 4303 | krop@novonordisk.com |
| Jannick Lindegaard Denholt | +45 3079 8519 | jlis@novonordisk.com |
| Daniel Bohsen | +45 3079 6376 | dabo@novonordisk.com |
| Frank Daniel Mersebach (US) | +1 609 235 8567 | fdni@novonordisk.com |
Company announcement No 58 / 2014
Company announcement No 58 / 2014 http://hugin.info/2013/R/1856969/650059.pdf
HUG#1856969
(0)
(0)Scroll down for more posts ▼